



ERLEADA (apalutamide)

#### Instructions

Please complete Part A and have your physician complete Part B. This form may not apply to your specific plan. Before completing the Prior Authorization form, check that this medication is on your plan's drug coverage list. Completion and submission is not a guarantee of approval. Any fees related to the completion of this form are the responsibility of the plan member. Drugs in the Prior Authorization Program may be eligible for reimbursement if the patient does not qualify for coverage under a primary plan or a government program. Drugs used for indications not approved by Health Canada may be denied. For Quebec plan members, RAMQ exception drug criteria may apply. The decision for approval versus denial is based on pre-defined clinical criteria, primarily based on Health Canada approved indication(s) and on supporting evidence-based clinical protocols. The plan member will be notified whether their request has been approved or denied. If you've already purchased the drug, please attach your original receipts along with a regular extended health care claim form.

### <u>Part A – Patient</u> Patient Information

Patient information						
First Name:			Last Name:			
Insurance Carrier N	lame/Number:					
Group Number:			Client ID:			
Date of Birth (YYYY/MM/DD):			Relationship: Employee Spouse Dependent			
Language: Eng	ilish  French		Gender: Male Female			
Address:						
City:		Province:		Postal Code:		
Email address:						
Telephone (home):		Telephone (cell):		Telephone (work):		
Please check any box that applies to the patient:  The patient is an over-age student dependent (i.e. attending University or College full-time). A copy of the enrolment document from the educational institution confirming full-time status is enclosed.  The patient is a spouse or a dependent over age 18. The patient has signed the authorization section below that allows Sun Life to obtain the additional medical information pertaining to this request.  Coordination of benefits						
Provincial Coverage	You applied for a drug that may be covered under a provincial plan. To find out if you qualify for coverage, speak to your doctor and apply to the province. Show the provincial response letter to your pharmacist when you receive it.					
Primary Coverage	Has the patient applied for reimbursement under a primary plan? Yes No N/A  What is the coverage decision of the drug? Approved Denied *Attach decision letter*					





ERLEADA (apalutamide)

#### **Authorization**

The answers on this form are true. I allow Sun Life to collect, use and disclose my personal information for three reasons. These reasons are plan administration, underwriting coverage and assessing claims. Sun Life may share (meaning collect and disclose) information with healthcare providers, hospitals, clinics, pharmacies, government programs, patient assistance programs, and any other organization with relevant information about me. Sun Life may also share information with insurers or reinsurers, and agents and service providers of Sun Life and the above parties. Sun Life will share my information only when necessary. My consent applies while this plan is in effect.

I agree that a photocopy or electronic version of this authorization is as valid as the original.

Plan Member Signature	Date
Patient Signature (if over 18 years of age)	Date





ERLEADA (apalutamide)

## Part B - Prescriber

Please see instructions on page 1 and complete all sections below. <u>Incomplete forms may result in automatic denial</u>. Please do **not** provide genetic test information or results.

ERLEADA (apalutamide)		New re	☐ New request ☐ Renewal request*		
DIN(s)	Dose	Administration (ex: oral, IV, etc)	Frequency	Duration	
Site of drug administra	_  ation:				
Home Phy	ysician's office/Private	Clinic Private Clinic (within Hos	spital - no public or g	government funding)	
Hospital (inpatient	) Hospital (out	nationt)			
		pationty			
Name of the hospital o	or private clinic:				
Address:					
City:	F	Province:	Postal code:		
* Please submit pro	of of prior coverage if a	vailable			
SECTION 2 – ELIGII	BILITY CRITERIA				
SECTION 2 - ELIGII	BILITY CRITERIA	e below criteria:			
Please indicate if	the patient satisfies th				
Please indicate if  Prostate Cancer – No	the patient satisfies th	n-Resistant	on ODDO) in the adult	AND	
Please indicate if  Prostate Cancer – No  For the treatr	rthe patient satisfies the n-Metastatic, Castration ment of non-metastatic	n-Resistant castration-resistant prostate cancer (nr			
1. Please indicate if  Prostate Cancer – No  For the treatr  The patient is	rthe patient satisfies the n-Metastatic, Castration ment of non-metastatic	n-Resistant			
1. Please indicate if  Prostate Cancer – No  For the treatr  The patient is  (PSADT) of 10	n-Metastatic, Castration ment of non-metastatic s considered to be at his 0 months or less, AND	n-Resistant castration-resistant prostate cancer (nr	a Prostate Specific A		
1. Please indicate if  Prostate Cancer - No  For the treatr  The patient is  (PSADT) of 10	n-Metastatic, Castration ment of non-metastatic is considered to be at his 0 months or less, AND	n-Resistant castration-resistant prostate cancer (no gh risk of developing metastases with a	a Prostate Specific A	ntigen Doubling Time	
1. Please indicate if  Prostate Cancer – No  For the treatr  The patient is (PSADT) of 10  The patient h  The patient h  ERLEADA will	n-Metastatic, Castration ment of non-metastatic s considered to be at hi o months or less, AND has experienced disease	n-Resistant castration-resistant prostate cancer (note of the castration of the castrate cancer (note of the castrate of the c	a Prostate Specific A omy, OR ation therapy (ADT),	ntigen Doubling Time	
1. Please indicate if  Prostate Cancer – No  For the treatr  The patient is  (PSADT) of 10  The patient h  ERLEADA will had a bilatera	rhe patient satisfies the n-Metastatic, Castration ment of non-metastatic sconsidered to be at his months or less, AND has experienced disease has experienced disease be used in combinatio	n-Resistant  castration-resistant prostate cancer (note of the progression despite bilateral orchiectors of the progression despite androgen deprivation of the progression despite androgen deprivation with a gonadotropin-releasing hormory	a Prostate Specific A omy, OR ation therapy (ADT),	ntigen Doubling Time	
1. Please indicate if  Prostate Cancer - No  For the treatr  The patient is (PSADT) of 10  The patient h  ERLEADA will had a bilaters	rhe patient satisfies the n-Metastatic, Castration ment of non-metastatic sconsidered to be at his months or less, AND has experienced disease as experienced disease.	n-Resistant  castration-resistant prostate cancer (note of the progression despite bilateral orchiectors of the progression despite androgen deprivation of the progression despite androgen deprivation with a gonadotropin-releasing hormory	a Prostate Specific A omy, OR ation therapy (ADT), a ne (GnRH) analog ui	ntigen Doubling Time	
1. Please indicate if  Prostate Cancer - No  For the treatr  The patient is (PSADT) of 10  The patient h  ERLEADA will had a bilaters  Prostate Cancer - Me	rhe patient satisfies the n-Metastatic, Castration ment of non-metastatic sconsidered to be at his months or less, AND has experienced disease as experienced disease.	n-Resistant castration-resistant prostate cancer (note of the progression despite bilateral orchiectors progression despite androgen deprivation with a gonadotropin-releasing hormors.)	a Prostate Specific A omy, OR ation therapy (ADT), a ne (GnRH) analog ui	ntigen Doubling Time	
1. Please indicate if  Prostate Cancer - No  For the treatr  The patient is  (PSADT) of 10  The patient h  ERLEADA will had a bilaters  Prostate Cancer - Me  For the treatr  The patient h	retastatic, Castration ment of non-metastatic seconsidered to be at his months or less, AND mas experienced disease mas experienced mas experienced ma	n-Resistant castration-resistant prostate cancer (note of the progression despite bilateral orchiectors progression despite androgen deprivation with a gonadotropin-releasing hormors.)	a Prostate Specific A omy, OR ation therapy (ADT), a ne (GnRH) analog un PC) in an adult, AND	ntigen Doubling Time	
1. Please indicate if  Prostate Cancer - No  For the treatr  The patient is  (PSADT) of 10  The patient h  ERLEADA will had a bilaters  Prostate Cancer - Me  For the treatr  The patient h	retastatic, Castration ment of non-metastatic seconsidered to be at his months or less, AND mas experienced disease mas experienced mas experienced ma	n-Resistant  castration-resistant prostate cancer (note of the progression despite bilateral orchiectors progression despite androgen deprivate note of the progression despite androgen deprivation with a gonadotropin-releasing hormore the progression despite androgen deprivation with a gonadotropin-releasing hormore the progression despite androgen deprivation with a gonadotropin-releasing hormore the progression despite and progressi	a Prostate Specific A omy, OR ation therapy (ADT), a ne (GnRH) analog un PC) in an adult, AND	ntigen Doubling Time	





ERLEADA (apalutamide)

OR  None of the above criteria applies.	
Relevant additional information:	
SECTION 3 - PRESCRIBER INFORMATION	
Physician's Name:	
Address:	
Tel:	Fax:
License No.:	Specialty:
Physician Signature:	Date:

### **SECTION 4 - RESPECTING YOUR PRIVACY**

Our Purpose is to help our Clients achieve lifetime financial security and live healthier lives. We collect, use and disclose your personal information to: develop and deliver the right products and services; enhance your experience and manage our business operations; perform underwriting, administration and claims adjudication; protect against fraud, errors or misrepresentations; tell you about other products and services; and meet legal and security obligations. We collect it directly from you, when you use our products and services, and from other sources. We keep your information confidential and only as long as needed. People who may access it include our employees, distribution partners such as advisors, service providers, reinsurers, or anyone else you authorize. At times, unless we're prohibited, they may be outside your jurisdiction and your information may be subject to local laws. You can always ask for your information and to correct it if needed. In most cases, you have a right to withdraw your consent, but we may not be able to provide the requested product or service. Read our Global Privacy Statement and local policy at <a href="https://www.sunlife.ca/privacy">www.sunlife.ca/privacy</a> or call us for a copy.

Questions? Please visit www.sunlife.ca or call toll-free 1-800-361-6212 Monday - Friday, 8 a.m. - 8 p.m. ET





ERLEADA (apalutamide)

### **SECTION 5 - CONTACT US**

	You can submit all pages of this form through the mysunlife mobile app or mysunlife.ca. Please use 'prior auth' as the
Ш	reference number.

OR

Please fax or mail the completed form to Sun Life Assurance Company of Canada ®

FAX: 1-855-342-9915 Mail:

Sun Life Assurance Company of Canada

Attention: Claims Dept. PO Box 11658 STN CV Montreal, QC H3C 6C1 Sun Life Assurance Company of

Canada

Attention: Claims Dept. PO Box 2010 STN Waterloo Waterloo, ON N2J 0A6